Sagimet Biosciences Secures $175M to Advance Acne Drug Pipeline
Event summary
- Sagimet Biosciences raised $175M in equity financing in April 2026, with participation from multiple institutional investors.
- Phase 3 clinical trial of denifanstat for moderate to severe acne planned for initiation in the second half of 2026.
- First-in-human Phase 1 clinical trial of FASN inhibitor TVB-3567 is ongoing.
- Cumulative cash expected to fund operations through 2028, including data readout of denifanstat Phase 3 trial.
The big picture
Sagimet's strategic pivot to dermatology, backed by a significant $175M equity raise, underscores the growing investment in novel treatments for moderate to severe acne. The company's focus on FASN inhibitors targets a market with unmet needs, particularly in oral treatment options. The upcoming Phase 3 trial of denifanstat will be a critical test of its potential to disrupt the acne treatment landscape.
What we're watching
- Clinical Timeline
- Whether Sagimet can initiate the Phase 3 trial of denifanstat in moderate to severe acne patients as planned in the second half of 2026.
- Financial Runway
- The pace at which Sagimet will deplete its cash reserves, given the expected funding through 2028.
- Market Differentiation
- How denifanstat's differentiated mode of action will position it against existing treatments in the acne market.